UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 79

Sortiert nach

Management of Recurrent Endometrioid Endometrial Carcinoma: An Overview

International journal of gynecological cancer, 2009-04, Vol.19 (3), p.314-320

2009

Link zum Volltext

Verfügbarkeit prüfen

Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer

European journal of cancer (1990), 2014-10, Vol.50 (15), p.2592-2601

2014

Link zum Volltext

Verfügbarkeit prüfen

Long-term results of weekly paclitaxel carboplatin induction therapy: An effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer

European journal of cancer (1990), 2013-04, Vol.49 (6), p.1254-1263

2013

Link zum Volltext

Verfügbarkeit prüfen

Management of Surgical Stage III and IV Endometrioid Endometrial Carcinoma: An Overview

International journal of gynecological cancer, 2009-04, Vol.19 (3), p.431-446

2009

Link zum Volltext

Verfügbarkeit prüfen

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients

Annals of oncology, 2011-06, Vol.22 (6), p.1346-1352

2011

Link zum Volltext

Verfügbarkeit prüfen

3BA Randomized MRC OV05/EORTC 55955 trial in recurrent ovarian cancer: early treatment based on increased serum CA125 alone versus delayed treatment based on conventional clinical indicators

European journal of cancer supplements, 2009, Vol.7 (3), p.3-3

2009

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: An EORTC Gynecological Cancer Cooperative Group study

Annals of oncology, 2001-07, Vol.12 (7), p.967-974

2001

Link zum Volltext

Verfügbarkeit prüfen

8006 Improved outcome after first line chemotherapy in BRCA1- and BRCA2-associated ovarian cancer compared with sporadic ovarian cancer patients

European journal of cancer supplements, 2009, Vol.7 (2), p.452-452

2009

Link zum Volltext

Verfügbarkeit prüfen

Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra

Annals of oncology, 2011-12, Vol.22 Suppl 8, p.viii33-viii39

2011

Link zum Volltext

Verfügbarkeit prüfen

The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer

Annals of oncology, 1990-07, Vol.1 (4), p.301-302

1990

Link zum Volltext

Verfügbarkeit prüfen

Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy

Gynecologic oncology, 1988-07, Vol.30 (3), p.307-312

1988

Link zum Volltext

Verfügbarkeit prüfen

Weekly high-dose cisplatin in malignant pleural mesothelioma

Annals of oncology, 1994-04, Vol.5 (4), p.373-374

1994

Link zum Volltext

Verfügbarkeit prüfen

Serum proteomic patterns for ovarian cancer monitoring

International journal of gynecological cancer, 2008-09, Vol.18 (5), p.985-995

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of High-Dose Epirubicin in Platinum-Pretreated Patients with Ovarian Carcinoma

Oncology, 1999-07, Vol.57 (1), p.10-16

1999

Link zum Volltext

Verfügbarkeit prüfen

Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)

European journal of cancer (1990), 2006-10, Vol.42 (15), p.2539-2548

2006

Link zum Volltext

Verfügbarkeit prüfen

Preoperative Predictors for Residual Tumor after Surgery in Patients with Ovarian Carcinoma

Oncology, 2007-01, Vol.72 (5-6), p.293-301

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix

Annals of oncology, 2007-02, Vol.18 (2), p.275-281

2007

Link zum Volltext

Verfügbarkeit prüfen

Dose-dense cisplatin/paclitaxel: a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer

European journal of cancer (1990), 2002-10, Vol.38 (15), p.2005-2013

2002

Link zum Volltext

Verfügbarkeit prüfen

Consolidation therapy for advanced ovarian cancer

Annals of oncology, 1998-02, Vol.9 (2), p.229-230

van der Burg, M.E.L.

1998

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus

Annals of oncology, 2003-08, Vol.14 (8), p.1253-1257

2003

Link zum Volltext

Verfügbarkeit prüfen

Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity

European journal of cancer (1990), 2002-02, Vol.38 (3), p.387-391

2002

Link zum Volltext

Verfügbarkeit prüfen

Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian Cancer

The New England journal of medicine, 1990-01, Vol.322 (2), p.89-94

1990

Link zum Volltext

Verfügbarkeit prüfen

Long-term survival in ovarian cancer: Mature data from The Netherlands joint study group for ovarian cancer

European journal of cancer & clinical oncology, 1991, Vol.27 (11), p.1367-1372

1991

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study

European journal of cancer (1990), 2001-09, Vol.37 (13), p.1624-1628

2001

Link zum Volltext

Verfügbarkeit prüfen

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies

European journal of cancer (1990), 2002-01, Vol.38 (1), p.205-213

2002

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(72)

Publikationsform

Artikel
(79)

Sprache

Englisch
(79)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Humans
(60)
Life Sciences & Biomedicine
(56)
Science & Technology
(56)
Female
(55)
Oncology
(50)
Middle Aged
(42)
Aged
(37)
Biological And Medical Sciences
(37)
Medical Sciences
(37)
Adult
(34)
Ovarian Neoplasms - Drug Therapy
(31)
Pharmacology. Drug Treatments
(29)
Chemotherapy
(28)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(26)
Cisplatin - Administration & Dosage
(25)
Antineoplastic Agents
(24)
Cisplatin
(17)
Cisplatin - Adverse Effects
(15)
Drug Administration Schedule
(15)
Prognosis
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Management of Recurrent Endometrioid Endometrial Carcinoma: An Overview

Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer

Long-term results of weekly paclitaxel carboplatin induction therapy: An effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer

Management of Surgical Stage III and IV Endometrioid Endometrial Carcinoma: An Overview

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients

3BA Randomized MRC OV05/EORTC 55955 trial in recurrent ovarian cancer: early treatment based on increased serum CA125 alone versus delayed treatment based on conventional clinical indicators

Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: An EORTC Gynecological Cancer Cooperative Group study

8006 Improved outcome after first line chemotherapy in BRCA1- and BRCA2-associated ovarian cancer compared with sporadic ovarian cancer patients

Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra

The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer

Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy

Weekly high-dose cisplatin in malignant pleural mesothelioma

Serum proteomic patterns for ovarian cancer monitoring

Phase I Study of High-Dose Epirubicin in Platinum-Pretreated Patients with Ovarian Carcinoma

Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)

Preoperative Predictors for Residual Tumor after Surgery in Patients with Ovarian Carcinoma

Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix

Dose-dense cisplatin/paclitaxel: a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer

Consolidation therapy for advanced ovarian cancer

Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus

Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity

Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian Cancer

Long-term survival in ovarian cancer: Mature data from The Netherlands joint study group for ovarian cancer

Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies

Suchergebnisse filtern